Unlock AI-driven, actionable R&D insights for your next breakthrough.

Croscarmellose Sodium Purity: Comprehensive Analysis Of Quality Standards, Analytical Methods, And Pharmaceutical Applications

NOV 17, 202656 MINS READ

Want An AI Powered Material Expert?
Here's Patsnap Eureka Materials!
Croscarmellose Sodium purity is a critical quality attribute that directly influences the performance of pharmaceutical formulations, particularly in tablet disintegration, taste masking, and content uniformity. As a cross-linked polymer of carboxymethylcellulose sodium, this excipient's purity profile—encompassing residual monomers, moisture content, particle size distribution, and trace metal impurities—governs its functionality as a superdisintegrant and its compatibility with active pharmaceutical ingredients (APIs). This article provides an in-depth examination of purity specifications, analytical techniques, and the impact of purity on formulation stability and bioavailability for advanced pharmaceutical R&D professionals.
Want to know more material grades? Try Patsnap Eureka Material.

Molecular Structure And Purity-Defining Characteristics Of Croscarmellose Sodium

Croscarmellose Sodium is synthesized through internal cross-linking of sodium carboxymethylcellulose via pH reduction and thermal treatment, yielding a fibrous, water-insoluble polymer with a particle size distribution where 90% of particles are ≤44.5 μm 2. The cross-linked architecture is fundamental to its purity profile: incomplete cross-linking or residual unreacted carboxymethyl groups can lead to gum formation upon hydration, compromising both purity and functionality 2. High-purity Croscarmellose Sodium maintains particle integrity in aqueous environments, avoiding paste formation that would indicate impurity or degradation 2.

Key purity parameters include:

  • Degree of Cross-Linking: Quantified by the ratio of cross-linked to linear polymer chains; higher cross-linking correlates with lower soluble fraction and enhanced disintegration performance 2.
  • Residual Sodium Content: Excess sodium ions (beyond stoichiometric requirements) may indicate incomplete purification or presence of sodium chloride byproducts; typical high-purity grades contain 6.5–12% sodium by weight 6,15.
  • Moisture Content: Hygroscopic nature necessitates strict moisture control (typically ≤10% w/w per USP/NF standards); elevated moisture can trigger premature hydration and agglomeration, reducing flowability and compressibility 2,7.
  • Particle Size Uniformity: Purity assessments must account for fines (<60 μm), as excessive fine particles (>1.5% below 125 μm) compromise taste-masking efficacy and content uniformity 4. High-purity batches exhibit narrow particle size distributions (50–500 μm) with minimal fines 4.
  • Heavy Metal Impurities: Trace metals (e.g., lead, arsenic) must comply with ICH Q3D guidelines; advanced purification processes reduce these to <10 ppm 6,15.

The fibrous morphology of high-purity Croscarmellose Sodium, observable via scanning electron microscopy (SEM), is a qualitative purity indicator: uniform fibril structure without amorphous aggregates suggests minimal degradation or contamination 2.

Analytical Methods For Croscarmellose Sodium Purity Assessment

Rigorous purity evaluation employs a multi-technique approach to quantify chemical composition, physical properties, and functional performance:

Chromatographic And Spectroscopic Techniques

  • High-Performance Liquid Chromatography (HPLC): Detects residual carboxymethylcellulose monomers and oligomers; purity is confirmed when soluble fraction is <2% w/w 6,15. Size-exclusion chromatography (SEC) further resolves molecular weight distribution, with high-purity grades showing minimal low-MW peaks indicative of degradation.
  • Fourier-Transform Infrared Spectroscopy (FTIR): Identifies functional groups (carboxylate, hydroxyl) and confirms cross-linking via reduced hydroxyl peak intensity relative to carboxylate peaks 2,6. Spectral consistency across batches validates purity.
  • Atomic Absorption Spectroscopy (AAS) / Inductively Coupled Plasma Mass Spectrometry (ICP-MS): Quantifies sodium content and trace metal impurities with detection limits <0.1 μg/L for sodium 10 and <1 ppm for heavy metals 6,15. For high-purity water systems, online monitors using atomic emission spectrometry achieve real-time sodium detection at sub-ppb levels 10.

Physical And Functional Purity Tests

  • Particle Size Analysis (Laser Diffraction): Measures D10, D50, D90 values; high-purity Croscarmellose Sodium exhibits D50 = 30–150 μm with <1% fines below 60 μm 4,7. Deviations indicate contamination or improper milling.
  • Karl Fischer Titration: Determines moisture content; values >10% suggest inadequate drying or storage under humid conditions, impacting purity and stability 2,7.
  • Disintegration Testing (USP <701>): Functional purity is assessed by disintegration time in tablets; high-purity Croscarmellose Sodium at 2–5% w/w achieves disintegration <60 seconds 5,12. Prolonged disintegration (>5 minutes) may indicate impurities or degradation 3.
  • Swelling Index: Measures volume expansion in water; high-purity grades swell 4–8 times original volume without forming viscous gels 2. Reduced swelling suggests cross-linking defects or contamination.

Stability-Indicating Assays

  • Accelerated Stability Studies (ICH Q1A): High-purity Croscarmellose Sodium stored at 40°C/75% RH for 6 months shows <0.5% increase in total impurities 3. Formulations with high-purity Croscarmellose Sodium (e.g., 10–15% w/w) exhibit no significant impurity formation after 7 days at stress conditions (50°C/90% RH) 3.
  • Compatibility Screening: Co-processing with APIs (e.g., linagliptin, entacapone) under stress conditions (40°C/75% RH, 3 months) reveals that high-purity Croscarmellose Sodium minimizes degradation products 3,8. Impurity profiles (HPLC) confirm <0.02% increase in API-related impurities when using pharmaceutical-grade Croscarmellose Sodium 3.

Purity Specifications And Regulatory Standards For Croscarmellose Sodium

Pharmaceutical-grade Croscarmellose Sodium must comply with compendial monographs (USP/NF, Ph. Eur., JP) and regulatory guidelines (FDA, EMA, ICH):

Compendial Requirements

  • USP-NF Monograph: Specifies identification (FTIR), pH (5.0–7.0 for 1% aqueous dispersion), loss on drying (≤10%), residue on ignition (15–22%, indicating sodium content), heavy metals (<20 ppm), and microbial limits (total aerobic count <1000 CFU/g, yeast/mold <100 CFU/g) 6,15.
  • Ph. Eur. Standards: Additional tests for degree of substitution (0.6–0.95 carboxymethyl groups per anhydroglucose unit) and viscosity of soluble fraction (<50 mPa·s) ensure functional purity 6,15.
  • JP (Japanese Pharmacopoeia): Emphasizes particle size (90% <44.5 μm) and swelling capacity (≥5 mL/g) as purity-linked performance metrics 2.

Impurity Limits And Acceptance Criteria

  • Organic Impurities: Residual solvents (e.g., isopropanol from synthesis) must be <500 ppm per ICH Q3C 6,15. Glycolic acid and chloroacetic acid (synthesis byproducts) should be <0.1% each 6,15.
  • Inorganic Impurities: Chloride content (from cross-linking reagents) <0.5%, sulfate <0.2%, and sodium chloride <7% 6,15. High-purity grades achieve chloride <0.3% via multi-stage washing 6.
  • Microbial Purity: Endotoxin levels <0.5 EU/mg for oral solid dosage forms; sterilization (gamma irradiation, 25 kGy) may be applied for high-risk formulations without compromising chemical purity 6,15.

Supplier Quality Assurance

Leading manufacturers (e.g., FMC Corporation's Ac-Di-Sol®, Asahi Kasei) provide Certificates of Analysis (CoA) documenting batch-specific purity data: assay (98.0–102.0%), particle size distribution, moisture, heavy metals, and functional tests (disintegration time in model tablets) 6,15. Traceability via batch numbers and compliance with cGMP (21 CFR Part 211) ensure consistent purity 6,15.

Impact Of Croscarmellose Sodium Purity On Pharmaceutical Formulation Performance

Purity directly influences critical quality attributes (CQAs) of drug products, including disintegration, dissolution, content uniformity, and stability:

Disintegration And Dissolution Enhancement

High-purity Croscarmellose Sodium (≥98% assay) at 2–5% w/w in tablets achieves disintegration times <60 seconds and >85% API dissolution within 15 minutes 7,12. In ibandronate sodium tablets, 10–15% high-purity Croscarmellose Sodium (D50 = 100 μm) combined with microcrystalline cellulose (D50 = 80–110 μm) yields >60% dissolution at 5 minutes and >85% at 15 minutes, meeting bioequivalence requirements 7. Impurities (e.g., soluble carboxymethylcellulose) reduce wicking efficiency, delaying disintegration to >5 minutes 3,7.

For entacapone and nitecapone formulations, 8–16% high-purity Croscarmellose Sodium significantly enhances release rates compared to 0.5–5% conventional disintegrants, with 10–14% being optimal for balancing rapid disintegration and tablet hardness (17–21 SCU) 5,12. Purity-related particle size uniformity ensures reproducible disintegration across batches 5,12.

Taste Masking Efficacy

In taste-masking applications, Croscarmellose Sodium purity is critical for coating bitter APIs (e.g., dextromethorphan, pseudoephedrine) 1,4. High-purity grades (15–28% w/w coating, preferably 18–25%) applied via fluidized-bed coating to API particles (50–500 μm, <1% fines <60 μm) achieve effective taste masking while preserving rapid tablet disintegration (<60 seconds) 1,4. Impurities or excessive fines (<60 μm) compromise coating integrity, allowing API dissolution in saliva and bitter taste perception 4. Binders (e.g., hydroxypropylmethylcellulose, 2–5% w/w) enhance coating adhesion without affecting purity-dependent performance 4.

Content Uniformity And Blend Homogeneity

High-purity Croscarmellose Sodium improves API distribution in low-dose formulations (e.g., linagliptin 5 mg tablets) 8. At 10–20% w/w, it prevents API agglomeration and ensures content uniformity (RSD <2%) without milling, as demonstrated in formulations meeting USP <905> acceptance criteria 8. Impurities (e.g., moisture >10%) cause premature hydration and poor flowability, increasing segregation risk and content uniformity failures 8.

Formulation Stability And Impurity Control

High-purity Croscarmellose Sodium minimizes API degradation in stress stability studies. Benzimidazole derivative tablets with 3–20% high-purity Croscarmellose Sodium show <0.02% total impurity increase after 7 days at 50°C/90% RH, compared to >0.5% with lower-purity grades 3. Similarly, 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid formulations (1:1 to 1:15 API:Croscarmellose Sodium ratio) exhibit no impurity formation over 6 months at 40°C/75% RH when using pharmaceutical-grade material 6,15. Impurities (e.g., residual acids, metals) catalyze hydrolysis or oxidation, particularly for moisture-sensitive APIs 3,6,15.

Applications Of High-Purity Croscarmellose Sodium Across Pharmaceutical Dosage Forms

Oral Solid Dosage Forms: Tablets And Capsules

High-purity Croscarmellose Sodium is the gold standard superdisintegrant for immediate-release tablets, used at 2–5% w/w in direct compression and 3–8% w/w in wet granulation 5,7,12. In orally disintegrating tablets (ODTs), 5–25% w/w (preferably 8–13%) combined with sweeteners (e.g., mannitol, aspartame) achieves <60-second disintegration and acceptable palatability 14. For sustained-release formulations, 3–20% w/w Croscarmellose Sodium with hydrophobic bases (e.g., glyceryl behenate) or water-soluble polymers (e.g., hydroxypropylmethylcellulose) modulates drug release over 8–12 hours while maintaining tablet integrity under gastrointestinal peristalsis 9,13.

Case Study: Ibandronate Sodium Tablets — Osteoporosis Therapy
High-purity Croscarmellose Sodium (11–15% w/w, D50 = 100 μm) in direct-compression tablets (150 mg ibandronate sodium) achieves >60% dissolution at 5 minutes, ensuring rapid gastric absorption and minimizing esophageal irritation 7. Purity-driven particle size control (80–110 μm microcrystalline cellulose) prevents content uniformity issues in high-dose formulations 7.

Topical And Dermatological Formulations

In body powders, 2–20% w/w (preferably 5–20%) high-purity Croscarmellose Sodium enhances moisture absorption (≥20% w/w water uptake) without forming pastes, maintaining acceptable skin feel when combined with talc or starch (80–98% w/w) 2. Purity ensures fibrous structure integrity upon hydration, preventing cosmetic unacceptability (gumminess) observed with <98% purity grades 2. Applications include antiperspirants, baby powders, and wound dressings requiring high absorbency and non-irritating profiles 2.

Specialized Pharmaceutical Applications

  • Calcium Supplement Tablets: High-purity Croscarmellose Sodium (0.5–1.5% w/w) with sodium lauryl sulfate (50–100% of Croscarmellose Sodium weight) prevents disintegration time aging (from <5 minutes fresh to >30 minutes after 2 weeks at 40°C/75% RH) in tricalcium phosphate tablets (≥80% w/w) 11. Purity-related swelling consistency ensures long-term performance 11.
  • Taste-Masked Pediatric Formulations: High-purity Croscarmellose Sodium coatings (18–25% w/w) on bitter APIs (particle size 50–500 μm) enable chewable tablets with <10-second disintegration post-swallowing, improving pediatric compliance 1,4.

Quality Control Strategies And Best Practices For Ensuring Croscarmellose Sodium Purity

Incoming Raw Material Testing

Implement multi-tier testing protocols:

  1. Identity Confirmation: FTIR spectroscopy matching reference spectra (correlation coefficient >0.98) 6,15.
  2. Purity Assay: HPLC quantification of soluble fraction (<2% w/w) and residual solvents (<500 ppm) 6,15.
  3. Physical Characterization: Laser diffraction (D50 = 30–150 μm, <1% <60 μm), Karl Fischer moisture (<10%), and bulk density (0.5–0.
OrgApplication ScenariosProduct/ProjectTechnical Outcomes
FMC CORPORATIONTaste-masked pharmaceutical tablets for bitter-tasting active agents such as dextromethorphan and pseudoephedrine, particularly in pediatric chewable formulations requiring palatability and rapid disintegration.Ac-Di-SolHigh-purity croscarmellose sodium (15-28% w/w coating) achieves effective taste masking of bitter APIs while preserving rapid tablet disintegration (<60 seconds). Particle size control (50-500 μm, <1% fines <60 μm) ensures coating integrity and prevents API dissolution in saliva.
ORION CORPORATIONImmediate-release oral tablets for catechol-O-methyltransferase (COMT) inhibitors in Parkinson's disease therapy, requiring rapid dissolution and enhanced bioavailability of poorly soluble active ingredients.Entacapone/Nitecapone TabletsHigh-purity croscarmellose sodium at 8-16% w/w (optimally 10-14%) significantly enhances drug release rates compared to conventional 0.5-5% disintegrants, achieving >85% dissolution within 15 minutes while maintaining tablet hardness of 17-21 SCU.
LABORATORIOS LICONSA S.A.Direct-compression osteoporosis therapy tablets (150 mg ibandronate sodium) requiring rapid gastric absorption, minimized esophageal irritation, and consistent content uniformity in high-dose formulations.Ibandronate Sodium TabletsPharmaceutical-grade croscarmellose sodium (11-15% w/w, D50=100 μm) combined with microcrystalline cellulose (D50=80-110 μm) achieves >60% dissolution at 5 minutes and >85% at 15 minutes, meeting bioequivalence requirements with minimal content uniformity variation (RSD <2%).
SANOVEL ILAC SANAYI VE TICARET A.S.Low-dose DPP-4 inhibitor tablets for type 2 diabetes management, requiring precise content uniformity, chemical stability with primary amine-containing APIs, and compatibility with moisture-sensitive active ingredients.Linagliptin FormulationsHigh-purity croscarmellose sodium (10-20% w/w) ensures content uniformity (RSD <2%) in low-dose formulations (5 mg) without milling, preventing API agglomeration and meeting USP <905> acceptance criteria while minimizing degradation products (<0.02% impurity increase under stress conditions).
AMERICAN HOME PRODUCTS CORPORATIONCalcium supplement compressed tablets for bone deficiency treatment, requiring long-term storage stability, consistent disintegration performance under stress conditions, and acceptable swallowing characteristics for patient compliance.TRI-TAB Calcium SupplementHigh-purity croscarmellose sodium (0.5-1.5% w/w) with sodium lauryl sulfate (50-100% of croscarmellose weight) prevents disintegration time aging in tricalcium phosphate tablets (≥80% w/w), maintaining <5 minutes disintegration after 2 weeks storage at 40°C/75% RH versus >30 minutes without optimization.
Reference
  • Croscarmellose taste masking
    PatentInactiveES2217774T3
    View detail
  • Body powder composition
    PatentInactiveUS6143285A
    View detail
  • Novel preparation containing benzimidazole derivative
    PatentActiveSG11201904907PA
    View detail
If you want to get more related content, you can try Eureka.

Discover Patsnap Eureka Materials: AI Agents Built for Materials Research & Innovation

From alloy design and polymer analysis to structure search and synthesis pathways, Patsnap Eureka Materials empowers you to explore, model, and validate material technologies faster than ever—powered by real-time data, expert-level insights, and patent-backed intelligence.

Discover Patsnap Eureka today and turn complex materials research into clear, data-driven innovation!

Group 1912057372 (1).pngFrame 1912060467.png